AU2018235021B2 - Detection, quantification and/or isolation of circulating tumor cells based on the expression of CD321 marker - Google Patents

Detection, quantification and/or isolation of circulating tumor cells based on the expression of CD321 marker Download PDF

Info

Publication number
AU2018235021B2
AU2018235021B2 AU2018235021A AU2018235021A AU2018235021B2 AU 2018235021 B2 AU2018235021 B2 AU 2018235021B2 AU 2018235021 A AU2018235021 A AU 2018235021A AU 2018235021 A AU2018235021 A AU 2018235021A AU 2018235021 B2 AU2018235021 B2 AU 2018235021B2
Authority
AU
Australia
Prior art keywords
cells
marker
subject
cell
ctcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018235021A
Other languages
English (en)
Other versions
AU2018235021A1 (en
Inventor
Cédric BLANPAIN
Ievgenia PASTUSHENKO
Panagiota SOTIROPOULOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Libre de Bruxelles ULB
Original Assignee
Universite Libre de Bruxelles ULB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Libre de Bruxelles ULB filed Critical Universite Libre de Bruxelles ULB
Publication of AU2018235021A1 publication Critical patent/AU2018235021A1/en
Application granted granted Critical
Publication of AU2018235021B2 publication Critical patent/AU2018235021B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018235021A 2017-03-16 2018-03-16 Detection, quantification and/or isolation of circulating tumor cells based on the expression of CD321 marker Active AU2018235021B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17161411.8 2017-03-16
EP17161411 2017-03-16
PCT/EP2018/056760 WO2018167312A1 (en) 2017-03-16 2018-03-16 Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker

Publications (2)

Publication Number Publication Date
AU2018235021A1 AU2018235021A1 (en) 2019-09-12
AU2018235021B2 true AU2018235021B2 (en) 2024-07-11

Family

ID=58387669

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018235021A Active AU2018235021B2 (en) 2017-03-16 2018-03-16 Detection, quantification and/or isolation of circulating tumor cells based on the expression of CD321 marker

Country Status (8)

Country Link
US (2) US12123877B2 (https=)
EP (2) EP4235179B1 (https=)
JP (1) JP7278595B2 (https=)
KR (1) KR102583603B1 (https=)
AU (1) AU2018235021B2 (https=)
CA (1) CA3054915A1 (https=)
IL (1) IL269315B2 (https=)
WO (1) WO2018167312A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019202788A1 (de) * 2019-03-01 2020-09-03 Robert Bosch Gmbh Verfahren zum Zählen von Zelltypen oder Zellmarkern in einer Probe, insbesondere in einer Blutprobe
JP2020144054A (ja) * 2019-03-07 2020-09-10 学校法人昭和大学 末梢血循環癌細胞の検出方法及び検出装置
KR102654518B1 (ko) * 2020-05-26 2024-04-04 가톨릭대학교 산학협력단 Lsp1 결핍 t 세포
CN113009135B (zh) * 2021-02-19 2024-04-02 山东省大健康精准医疗产业技术研究院 一种检测cd47的管式磁微粒化学发光免疫定量试剂盒及其制备方法与应用
CA3233047A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Methods for disease assessment using drain fluid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130737A1 (en) * 2005-06-02 2006-12-07 Immunivest Corporation A method for assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
WO2013148450A1 (en) * 2012-03-30 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Use of jam-a in diagnosing and treating leukemia
WO2014120265A1 (en) * 2013-02-02 2014-08-07 Duke University Method of isolating circulating tumor cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US8980568B2 (en) * 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
AU2004286307A1 (en) 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
CA2628390A1 (en) * 2005-11-02 2007-05-18 The Regents Of The University Of Michigan Molecular profiling of cancer
CA2572530A1 (en) * 2005-12-30 2007-06-30 Centocor, Inc. A method for determining the phenotype of cells
GB0808413D0 (en) 2008-05-09 2008-06-18 Univ Nottingham Stabilisation of blood cell conjugates
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
EP2199798A1 (en) * 2008-12-18 2010-06-23 Universite Libre De Bruxelles Diagnostic method and kit of circulating tumor cells
EP2455403A1 (en) * 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
AU2014364520B2 (en) * 2013-12-20 2020-01-02 The General Hospital Corporation Methods and assays relating to circulating tumor cells
CN112358943A (zh) * 2015-01-21 2021-02-12 新加坡科技研究局 用于基于大小回收稀有细胞的以柱为基础的装置和方法，及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130737A1 (en) * 2005-06-02 2006-12-07 Immunivest Corporation A method for assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
WO2013148450A1 (en) * 2012-03-30 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Use of jam-a in diagnosing and treating leukemia
WO2014120265A1 (en) * 2013-02-02 2014-08-07 Duke University Method of isolating circulating tumor cells

Also Published As

Publication number Publication date
EP3596467A1 (en) 2020-01-22
IL269315A (en) 2019-11-28
EP4235179C0 (en) 2025-08-13
EP4235179A3 (en) 2023-11-15
JP2020512549A (ja) 2020-04-23
WO2018167312A1 (en) 2018-09-20
EP3596467B1 (en) 2023-09-27
AU2018235021A1 (en) 2019-09-12
EP3596467C0 (en) 2023-09-27
IL269315B1 (en) 2025-01-01
US20210190787A1 (en) 2021-06-24
IL269315B2 (en) 2025-05-01
KR20190142330A (ko) 2019-12-26
EP4235179A2 (en) 2023-08-30
US20250027946A1 (en) 2025-01-23
US12123877B2 (en) 2024-10-22
JP7278595B2 (ja) 2023-05-22
CA3054915A1 (en) 2018-09-20
EP4235179B1 (en) 2025-08-13
KR102583603B1 (ko) 2023-10-05

Similar Documents

Publication Publication Date Title
US20250027946A1 (en) Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker
Gubin et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Aldeghaither et al. A mechanism of resistance to antibody-targeted immune attack
US9846162B2 (en) Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
EP3634584B1 (en) Tumor-infiltrating t-cells for use in the treatment of cancer
WO2018089386A1 (en) Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
JP2021527082A (ja) 新規な免疫チェックポイント阻害剤
CN104823054A (zh) 对修饰后自体表位的抗肿瘤免疫应答
CA2990520C (en) Methods for detecting tissue infiltrating nk cells
CN110945030A (zh) 使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法
KR20180110133A (ko) 일차 위선암의 체세포 프로모터 랜드스케이프를 나타내는 후성유전학적 프로파일링
CN103492582A (zh) 用于测定HE4a的组合物和方法
US20240302349A1 (en) Methods of assessing or monitoring a response to a cell therapy
JP2024509530A (ja) 赤血球障害を治療する方法
WO2022150447A1 (en) Partial-emt signature for prediction of high-risk histopathologic features and cancer outcomes across demographic populations
JP2011516840A (ja) 可溶性ｃｄ２００に関するアッセイ法
WO2024083790A1 (en) Cd207 dendritic cells as a biomarker for tumoural progression and therapeutic target
Lau et al. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy
WO2026039869A1 (en) "predicting responders to cancer therapy"
WO2022214564A1 (en) Methods and kits for diagnosing cancer and predicting response to treatment based on cenp-a labelling
CN120769748A (zh) 用于诊断和治疗卵巢癌的方法
Maio et al. High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients
Gwin et al. Immunologic Monitoring in Immuno‐Oncology
Galluzzi et al. An immunosurveillance mechanism controls cancer cell ploidy. Supplementary Material.
Roussy Tumor sialylation controls effective anti-cancer immunity in breast cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)